Device Trial Radar · NCT03238469
Microwave Ablation in Mild Axillary Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Jun 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
Sep 1, 2017
Primary completion
Apr 1, 2018
Study completion Apr 1, 2018
Sponsor
- Lead sponsor
- M.B.A. van DoornAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Erasmus Medical Center
- First posted
- Aug 3, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
With microwave ablation (MWA), using the heat generated from electromagnetic waves in the microwave energy spectrum, hair follicles and apocrine glands in the (hypo)dermis are ablated through thermolysis. MWA was recently approved for the treatment of axillary hyperhidrosis (miraDry) and removal of axillary hair (miraSmooth). By permanent removal of hairs and sweat glands, the investigators hypothesize a beneficial and long-term sustainable preventive effect of MWA in HS patients.
Conditions
- Hidradenitis Suppurativa
- Acne Inversa
Interventions
Microwave ablationDevice
A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hidradenitis Suppurativa Clinical Response (HiSCR50)Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Erasmus University Medical Center
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.